Results of long-term follow-up of patients with chronic gastritis after H. pylori eradication
Abstract
The aim of publication. To analyze approach for long-term management of patients with chronic gastritis after H. pylori eradication for stomach cancer prevention by the example of clinical cases.
Key points. The management approach of patients with chronic gastritis after eradication of H. pylori is presented by the example of patients with various risk of development of stomach cancer. In one and half year after successful eradication therapy in 57 year-old female patient mild atrophy and intestinal metaplasia of antrum without atrophy and intestinal metaplasia of corpus of the stomach was confirmed. At absence of other risk factors for cancer development further endoscopic follow-up is not required. Monitoring of 62 year-old male patient after successful eradication for 5 years has shown stable morphological pattern without progression of premalignant lesions. Taking into account both severe atrophy and intestinal metaplasia of antral region and mild atrophy of body of the stomach, as well as positive family history, esophagogastroscopy with biopsy is recommended once per year to this patient.
Conclusion. Prognosis and management approach of patients after eradication of H. pylori infection are determined by chronic gastritis in relation to severity of atrophy and intestinal metaplasia of antral region and corpus of the stomach, along with other risk factors for cancer development e.g. positive family history.
About the Authors
T. L. Lapina
Sechenov First Moscow state medical university, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Lapina Tatyana L — MD, lecturer, Chair of internal diseases propedeutics, medical faculty
119991, Moscow, street Pogodinskaya, 1, bld. 1.
A. S. Tertychny
Sechenov First Moscow state medical university, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
E. R. Nasretdinova
Sechenov First Moscow state medical university, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Nasretdinova Elmira R — doctoral candidate, Chair of internal diseases propedeutics, medical faculty
I. M. Kartavenko
Sechenov First Moscow state medical university, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Kartavenko Ilona M — research associate, Scientific and educational clinical center of innovative therapy
A. V. Paraskevova
Sechenov First Moscow state medical university, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Ye. Yu. Yur’yeva
Sechenov First Moscow state medical university, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
O. A. Storonova
Sechenov First Moscow state medical university, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
A. S. Trukhmanov
Sechenov First Moscow state medical university, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
V. T. Ivashkin
Sechenov First Moscow state medical university, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Correa P., Blanca Piazuelo M. The gastric precancerous cascade. J Clin Exp Pathol 2013; 3:147.
2. Malfertheiner P., Megraud F., O’Morain C., et al. Management of Helicobacter pylori infection - the Maastricht IV / Florence Consensus Report. Gut 2012; 61:646-664.
3. Baranskaya Ye.K., Ivashkin V.T. Clinical spectrum of premalignant diseases of the stomach. Ros zhurn gastroenterol gepatol koloproktol 2002; 12(3):7-14.
4. Ivashkin V.T., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Drapkina O.M., Abdulkhakov R.A., Alekseyeva O.P., Alekseyenko S.A., Zaytsev S.V., Korochanskaya N.V., Kurilovich S.A., Mayev I.V., Osipenko M.F., Sayfutdinov R.G., Sarsenbayeva A.S. Practical steps on prevention of stomach cancer in the Russian Federation: algorithm of management of chronic H.pylori-associated gastritis (Proceedings and resolution of experts panel, December, 9, 2013). Ros zhurn gastroenterol gepatol koloproktol 2014; 24(2):102-4.
5. Park Y.H., Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 2015;20(1):25-40.
6. Parkin D.M. The global health burden of infectionassociated cancers in the year 2002. Int J Cancer 2006; 118:3030-44.
7. Ohata H., Kitauchi S., Yoshimura N., Mugitani K., Iwane M., Nakamura H., et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2004;109:138-43.
8. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345(11):784-9.
9. de Vries A.C., Kuipers E.J. Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. Helicobacter. 2007; 12(suppl 2):22-31.
10. Yoon H., Kim N. Diagnosis and management of high risk group for gastric cancer. Gut Liver. 2015; 9(1):5-17.
11. Rugge M., Correa P., di Mario F., El-Omar E., Fiocca R., Geboes K. et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008; 40(8):650-8. 12. Rugge M., Meggio A., Pennelli G. et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56(5): 631–636.
12. Dinis-Ribeiro M., Areia M., de Vries A.C. et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44(1): 74-94.
13. Iijima K., Abe Y., Kikuchi R., Koike T., Ohara S., Sipponen P., Shimosegawa T. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol 2009; 15(7):853-9.
14. Lapina T.L., Kon’kov M.Yu., Ivashkin V.T., Pyurveyeva K.V., Sklyanskaya O.A., Serova A.G. Late results of H. pylori eradication at atrophic gastritis. Vrach 2009; 3:47-50.
15. Gisbert J.P., Khorrami S., Calvet X., Pajares J.M. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2004;16(1):89-99.
16. Steinijans V.W., Huber R., Hartmann M., et al. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther. 1996; 34 (Suppl.1):S31-50.
17. Ivashkin V.T., Mayev I.V., Lapina T.L., Sheptulin A.A. et al., Diagnostics and treatment of Helicobacter pylori infection in adults: Guidelines of the Russian Gastroenterological Association. Ros zhurn gastroenterol gepatol koloproktol 2012; 22(1):87-9.
18. Rokkas T., Sechopoulos P., Pistiolas D., Margantinis G., Koukoulis G. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol. 2010; 22(9):1128-33.
Review
For citations:
Lapina T.L., Tertychny A.S., Nasretdinova E.R., Kartavenko I.M., Paraskevova A.V., Yur’yeva Ye.Yu., Storonova O.A., Trukhmanov A.S., Ivashkin V.T. Results of long-term follow-up of patients with chronic gastritis after H. pylori eradication. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(4):101-108. (In Russ.)
Views:
98
Email this article 
